(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry - 2If everyone on Earth sat in the ocean at once, how much would sea level rise?
- 3Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- 4Woman shocked to welcome baby after experiencing stomach pain on Christmas
- 5Cyprus urges hotels to open up, pours funding into tourism
- 2024 Watch Gathering: The Best Watches of the Year
- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- Iran War Derails The Automotive Industry
- Vote In favor of Your #1 sort of film
- It's time for Artemis II to break Apollo 13's distance record. What to know about the moon flyby
- Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- Telecommute Arrangement: What's Pivotal for Your Efficiency?
- France honors the victims of the Paris attacks' night of terror 10 years on
